MAPK3 and B-cell chronic lymphocytic leukemia: As expected, we found that MEK inhibition resulted in a concentration‐dependent reduction in ERK1/2 (pT202/Y204), a downstream substrate of MEK, in CD19+ CLL cells (Fig. 2A, left panel, green curves).